Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Eprodisate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprodisate SCHEMBL2288868 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL218551 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL4422542 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL2519328 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL12979823 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL218553 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL2522165 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| Eprodisate SCHEMBL11909837 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| SCHEMBL917845 | 0.92 | ALDH1A1 (0.67) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA | |
| SCHEMBL921255 | 0.89 | TSHR (0.63) | ALDH1A1TSHRSMN1; SMN2GMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463589-B1 | HEMP HURD-BASED NONWOVEN MATERIAL AND RELATED PRODUCTION METHOD | TEXOL S R L (IT) | 2025-12-24 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4277958-B1 | SHEAR-THINNING GEL COMPOSITIONS FOR PREPARING ELECTRONICALLY CONDUCTIVE INKS | EMPA EIDGENOESSISCHE MAT & FORSCHUNGSANSTALT (CH) | 2024-11-13 | — | — | EP | claimed |
| EP-4121073-B1 | BIOCOMPOSITES COMPRISING PROBIOTICS, COLLAGEN AND BACTERIAL EXTRACELLULAR POLYSACCHARIDE AND USES THEREOF | BIOSEARCH S A (ES) | 2024-07-03 | — | — | EP | claimed |
| CN-117720439-A | Preparation method of 1, 3-propanedisulfonyl fluoride | 河北圣泰材料股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-3393496-B1 | LONG-ACTING GLP-1R AGONIST AS A THERAPY OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS | UNIV JOHNS HOPKINS (US) | 2023-10-11 | — | — | EP | claimed |
| EP-2944308-A1 | Formulations and methods for treating chronic infection | Kiacta Sàrl (CH) | 2015-11-18 | — | — | EP | claimed |
| EP-1885350-B9 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-06-17 | — | — | EP | claimed |
| EP-1885350-B1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-03-04 | — | — | EP | claimed |
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | claimed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | claimed |
| WO-2007125385-A2 | TREATMENT OF RENAL DISORDERS, DIABETIC NEPHOPATHY AND DYSLIPIDEMIAS | NEUROCHEM (INTERNATIONAL) LIMITED (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070238788-A1 | Treatment of renal disorders, diabetic nephropathy and dyslipidemias | KIACTA SARL (CH) | 2007-10-11 | — | — | US | claimed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | claimed |
| WO-2007004072-A2 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | WO | claimed |
| US-20060252829-A1 | Formulations and methods for treating amyloidosis | KIACTA SARL (CH) | 2006-11-09 | — | — | US | claimed |
| US-20060167095-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-07-27 | — | — | US | claimed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | claimed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | claimed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167095-A1 | Method for treating amyloidosis | TTR, IAPP, APP | ALDH1A1 2877/4885TSHR 3807/4885SMN1; SMN2 368/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | ALDH1A1 687/4885TSHR 1743/4885SMN1; SMN2 673/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | ALDH1A1 78/4885TSHR 4762/4885SMN1; SMN2 304/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | ALDH1A1 78/4885TSHR 4762/4885SMN1; SMN2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.